TEAM
The GlucoSet management team combines clinical insight with start-up and scale-up experience.
BOARD
All stock in GlucoSet is owned by the employees, board members and the investors. The company’s largest investors are Norsk Innovasjonskapital IV AS, EIC Fund and the Swiss Diabetes Venture Fund.
ADVISORY BOARD
Our advisory board is hand-picked with international experts that give valuable external input on external issues.
Luc Foubert, MD PhD is a chief intensivist at OLV Hospital Aalst (Belgium). He has been heavily involved in CGM development for the ICU in the past, and is thus intimately familiar with failed past approaches. He has co-authored 97 papers.
Marcus Schultz, MD PhD is a professor in experimental intensive care medicine at the University of Amsterdam, and is involved in implementation of new strategies and technologies in modern ICUs. He has co-authored more than 300 published papers.
Fedrico Bilotta, MD PhD is a recognized anasthesiologist working within critical care and pain medicine at the 'Sapienza' University of Rome and has published more than 70 papers in recognized journals, among other things on glycemic control in the ICU.
BACKERS
GlucoSet has been supported directly or through the Norwegian University of Science and Technology by the following entities:
